Biomarkers and surrogate end points in clinical trials of tuberculosis treatment - Reply to Davies et al.

被引：0
|
作者：
Walzl, Gerhard
Mistry, Rohit
Dockrell, Hazel M.
van Helden, Paul D.
Cliff, Jacqueline M.
机构：
[1] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England
[2] Univ Stellenbosch, Fac Hlth Sci, Dept Med Biochem, ZA-7505 Tygerberg, South Africa
来源：
JOURNAL OF INFECTIOUS DISEASES | 2007年 / 196卷 / 04期
关键词：
D O I：
10.1086/519746
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：649 / 650
页数：2
相关论文
共 50 条
  • [21] Clinical trials and surrogate end points: lessons from the ENHANCE trial
    Farmer, John Alan
    FUTURE LIPIDOLOGY, 2008, 3 (04): : 353 - 357
  • [22] Surrogate end-points for treatment trials of hepatitis B virus
    Griffiths, P. D.
    REVIEWS IN MEDICAL VIROLOGY, 2010, 20 (04) : 199 - 201
  • [23] Biomarkers of myocardial injury as surrogate end-points for remote ischemic conditioning trials
    Iliodromitis, Efstathios K.
    Farmakis, Dimitrios
    Kremastinos, Dimitrios T.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 149 (03) : 379 - 379
  • [24] ON-FARM TRIALS AS 'INFECTION POINTS'? A RESPONSE TO WALL ET AL.
    Andersson, J. A.
    Krupnik, T. J.
    De Roo, N.
    EXPERIMENTAL AGRICULTURE, 2019, 55 (02) : 195 - 199
  • [25] Treatment of tuberculosis in Haiti - Desvarieux et al. respond
    Desvarieux, M
    Johnson, WD
    Pape, JW
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2001, 91 (10) : 1547 - 1547
  • [26] Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges
    Heinonen, Therese M.
    Aamer, Maira
    Marshall, Cameron
    Black, Donald M.
    Tardif, Jean-Claude
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (08) : 989 - 994
  • [27] Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment"
    Diacon, Andreas H.
    De Jager, Veronique R.
    Dawson, Rodney
    Narunsky, Kim
    Vanker, Naadira
    Burger, Divan A.
    Everitt, Daniel
    Pappas, Frances
    Nedelman, Jerry
    Mendel, Carl M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [28] Reply: Davies et al. (2012), Hydraulic fractures: How far can they go?
    Davies, Richard J.
    Foulger, Gillian R.
    Mathias, Simon
    Moss, Jennifer
    Hustoft, Steinar
    Newport, Leo
    MARINE AND PETROLEUM GEOLOGY, 2013, 43 : 519 - 521
  • [29] Response to Sarpal et al.: Importance of Neuroimaging Biomarkers for Treatment Development and Clinical Practice
    Gong, Qiyong
    AMERICAN JOURNAL OF PSYCHIATRY, 2016, 173 (07): : 733 - 734
  • [30] INCOMPLETE MULTIRESPONSE DESIGNS AND SURROGATE END-POINTS IN CLINICAL-TRIALS
    SEN, PK
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1994, 42 (1-2) : 161 - 186
12345